Sonoma Pharmaceuticals, Inc. (SNOA) — Financial statements
Income statement, balance sheet, and cash flow for Sonoma Pharmaceuticals, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2026 | 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 20↑36.7% | 14↑12.2% | 13↓4.0% | 13↑5.1% | 13 | |
| Cost of Revenue | 12↑37.3% | 9↑10.4% | 8↓9.2% | 9↑1.9% | 9 | |
| Gross Profit | 7↑35.7% | 5↑15.2% | 5↑6.0% | 4↑12.1% | 4 | |
| Operating Expenses | ||||||
| R&D Expenses | 2↑25.2% | 2↓3.0% | 2↑803.9% | 0.21↑65.6% | 0.13 | |
| General & Administrative Expenses | 0.00↓100.0% | 7 | 0.00 | 0.00 | 0.00 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 0.19 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 8↑3.3% | 7↓2.8% | 8↓14.3% | 9↓9.4% | 10 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 10↑7.6% | 9↓2.9% | 9↑4.4% | 9↓8.4% | 10 | |
| Total Costs & Expenses | 22↑22.2% | 18↑3.2% | 17↓2.3% | 18↓3.6% | 19 | |
| Operating Results | ||||||
| Operating Income | -2↑33.7% | -4↑21.1% | -5↓2.9% | -5↑22.4% | -6 | |
| Depreciation & Amortization | 0.14↑0.7% | 0.14↓21.6% | 0.18↑40.8% | 0.13↓32.8% | 0.19 | |
| EBITDA | -2↑31.1% | -4↑21.1% | -5↓1.8% | -4↑22.0% | -6 | |
| EBIT | -2↑33.7% | -4↑21.1% | -5↓2.9% | -5↑22.4% | -6 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.02↑260.0% | -0.01 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.02 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | -0.96↓219.3% | 0.80↑343.3% | -0.33↑46.3% | -0.61↓230.9% | 0.47 | |
| Income Before Tax | -3↓17.6% | -3↑42.2% | -5↑3.0% | -5↑4.3% | -5 | |
| Income Tax Expense | 0.24↓55.6% | 0.55↑380.6% | -0.20↓493.9% | -0.03↑90.1% | -0.33 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -3↑8.2% | -3↑28.5% | -5↑6.1% | -5↓1.3% | -5 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -3↑8.2% | -3↑28.5% | -5↑6.1% | -5↓1.3% | -5 | |
| Bottom-Line Net Income | -3↑8.2% | -3↑28.5% | -5↑6.1% | -5↓1.3% | -5 | |
| EPS (Basic) | -1.89↑32.3% | -2.79↑47.6% | -5.32↑65.0% | -15.18↑20.8% | -19.17 | |
| EPS (Diluted) | -1.89↑32.3% | -2.79↑47.6% | -5.32↑65.0% | -15.18↑20.8% | -19.17 | |
| Weighted Average Shares | 2↑35.7% | 1↑36.5% | 0.91↑167.8% | 0.34↑27.9% | 0.27 | |
| Weighted Average Diluted Shares | 2↑35.7% | 1↑36.5% | 0.91↑167.8% | 0.34↑27.9% | 0.27 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.